Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
Paccaly AJ, Kovalenko P, Parrino J, Boyapati A, Xu C, van Hoogstraten H, Ishii T, Davis JD, DiCioccio AT. Paccaly AJ, et al. Among authors: boyapati a. J Clin Pharmacol. 2021 Jan;61(1):90-104. doi: 10.1002/jcph.1703. Epub 2020 Jul 29. J Clin Pharmacol. 2021. PMID: 32726514 Free PMC article. Clinical Trial.
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, van Hoogstraten H, Boklage SH, Sadeh J, Graham NMH, Boyapati A. Gabay C, et al. Among authors: boyapati a. Arthritis Res Ther. 2020 Apr 7;22(1):70. doi: 10.1186/s13075-020-02163-6. Arthritis Res Ther. 2020. PMID: 32264972 Free PMC article. Clinical Trial.
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, Burmester GR, Lam G, Kimura T, Sadeh J, Weinreich DM, Yancopoulos GD, Graham NMH. Boyapati A, et al. Arthritis Rheumatol. 2020 Sep;72(9):1456-1466. doi: 10.1002/art.41299. Epub 2020 Aug 25. Arthritis Rheumatol. 2020. PMID: 32343882 Free PMC article.
Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis.
Kovalenko P, Paccaly A, Boyapati A, Xu C, St John G, Nivens MC, Davis JD, Rippley R, DiCioccio AT. Kovalenko P, et al. Among authors: boyapati a. CPT Pharmacometrics Syst Pharmacol. 2020 Jul;9(7):405-416. doi: 10.1002/psp4.12534. Epub 2020 Jun 20. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32453485 Free PMC article.
UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab.
Lin N, Damask A, Boyapati A, Hamilton JD, Hamon S, Ternes N, Nivens MC, Penn J, Lopez A, Reid JG, Overton J, Shuldiner AR, Abecasis G, Baras A, Paulding C. Lin N, et al. Among authors: boyapati a. Pharmacogenomics J. 2022 May;22(3):160-165. doi: 10.1038/s41397-022-00269-5. Epub 2022 Feb 11. Pharmacogenomics J. 2022. PMID: 35149777 Free PMC article.
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
Sivapalasingam S, Lederer DJ, Bhore R, Hajizadeh N, Criner G, Hosain R, Mahmood A, Giannelou A, Somersan-Karakaya S, O'Brien MP, Boyapati A, Parrino J, Musser BJ, Labriola-Tompkins E, Ramesh D, Purcell LA, Gulabani D, Kampman W, Waldron A, Ng Gong M, Saggar S, Sperber SJ, Menon V, Stein DK, Sobieszczyk ME, Park W, Aberg JA, Brown SM, Kosmicki JA, Horowitz JE, Ferreira MA, Baras A, Kowal B, Thomas DiCioccio A, Akinlade B, Nivens MC, Braunstein N, Herman GA, Yancopoulos GD, Weinreich DM. Sivapalasingam S, et al. Among authors: boyapati a. Clin Infect Dis. 2022 Aug 24;75(1):e380-e388. doi: 10.1093/cid/ciac153. Clin Infect Dis. 2022. PMID: 35219277 Free PMC article. Clinical Trial.
The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients.
McAleavy M, Zhang Q, Ehmann PJ, Xu J, Wipperman MF, Ajithdoss D, Pan L, Wakai M, Simonson R, Gadi A, Oyejide A, Hamon SC, Boyapati A, Morton LG, Shavlakadze T, Kyratsous CA, Glass DJ. McAleavy M, et al. Among authors: boyapati a. Mol Cell Biol. 2022 Jan 20;42(1):e0046721. doi: 10.1128/MCB.00467-21. Epub 2021 Nov 1. Mol Cell Biol. 2022. PMID: 34723652 Free PMC article. Clinical Trial.
34 results